NZ529115A - Use of probucol, ascorbic acid, vitamin E, dipyridamole and mopidamol for treatment and prevention of NO-dependent microcirculation disorders - Google Patents

Use of probucol, ascorbic acid, vitamin E, dipyridamole and mopidamol for treatment and prevention of NO-dependent microcirculation disorders

Info

Publication number
NZ529115A
NZ529115A NZ529115A NZ52911502A NZ529115A NZ 529115 A NZ529115 A NZ 529115A NZ 529115 A NZ529115 A NZ 529115A NZ 52911502 A NZ52911502 A NZ 52911502A NZ 529115 A NZ529115 A NZ 529115A
Authority
NZ
New Zealand
Prior art keywords
dipyridamole
treatment
bmy
production
mopidamol
Prior art date
Application number
NZ529115A
Other languages
English (en)
Inventor
Wolfgang Eisert
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NZ529115A publication Critical patent/NZ529115A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ529115A 2001-04-20 2002-04-13 Use of probucol, ascorbic acid, vitamin E, dipyridamole and mopidamol for treatment and prevention of NO-dependent microcirculation disorders NZ529115A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119680A DE10119680A1 (de) 2001-04-20 2001-04-20 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation
PCT/EP2002/004129 WO2002085368A2 (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders

Publications (1)

Publication Number Publication Date
NZ529115A true NZ529115A (en) 2005-08-26

Family

ID=7682292

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ529115A NZ529115A (en) 2001-04-20 2002-04-13 Use of probucol, ascorbic acid, vitamin E, dipyridamole and mopidamol for treatment and prevention of NO-dependent microcirculation disorders

Country Status (10)

Country Link
EP (1) EP1389112A2 (es)
JP (1) JP2004525979A (es)
AU (1) AU2002338396B2 (es)
CA (1) CA2444370A1 (es)
DE (1) DE10119680A1 (es)
HU (1) HUP0303754A3 (es)
IL (1) IL158091A0 (es)
MX (1) MXPA03009506A (es)
NZ (1) NZ529115A (es)
WO (1) WO2002085368A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4341C1 (ro) * 2013-11-21 2015-11-30 Ион МЕРЕУЦЭ Sirop pentru tratamentul stărilor precanceroase gastrice

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1846058T3 (pl) * 2005-02-11 2009-12-31 Nolabs Ab Produkt, sposób i zastosowanie go do leczenia neuropatii z wydzielaniem tlenku azotu
TWI725008B (zh) * 2015-01-28 2021-04-21 瑞采生技有限公司 用於增強ＰＰＡＲγ表現及核轉位之化合物及其醫療用途
CN113244395B (zh) * 2020-02-10 2024-07-23 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1711892A1 (ru) * 1989-01-06 1992-02-15 Московский медицинский стоматологический институт им.Н.А.Семашко Способ лечени диабетической ангиопатии
SU1711894A1 (ru) * 1989-08-08 1992-02-15 Детская Клиническая Больница N1 Способ лечени декомпенсированных форм стенозирующего ларинготрахеита у детей
IT1239064B (it) * 1990-05-14 1993-09-20 Fidia Spa Uso terapeutico del dipiridamolo
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
WO1995006470A1 (en) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
WO2000067737A2 (en) * 1999-05-07 2000-11-16 The Brigham And Women's Hospital, Inc. USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4341C1 (ro) * 2013-11-21 2015-11-30 Ион МЕРЕУЦЭ Sirop pentru tratamentul stărilor precanceroase gastrice

Also Published As

Publication number Publication date
MXPA03009506A (es) 2004-02-12
IL158091A0 (en) 2004-03-28
HUP0303754A2 (hu) 2004-03-01
JP2004525979A (ja) 2004-08-26
DE10119680A1 (de) 2002-11-14
WO2002085368A2 (en) 2002-10-31
AU2002338396B2 (en) 2007-10-18
CA2444370A1 (en) 2002-10-31
HUP0303754A3 (en) 2006-02-28
WO2002085368A3 (en) 2003-02-20
EP1389112A2 (en) 2004-02-18

Similar Documents

Publication Publication Date Title
US20080113934A1 (en) Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
US20090192123A1 (en) Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of Thrombin and/or by elevated expression of Thrombin receptors
US20080188497A1 (en) Dipyridamole, Acetylsalicylic Acid, and Angiotensin II Antagonist Pharmaceutical Compositions
US20080076786A1 (en) Use of radical-scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
AU2002338396B2 (en) Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
AU2002338396A1 (en) Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
US20050038003A1 (en) Use of dipyridamole, acetylsalicylic acid and an angiotensin II antagonist for treatment and prevention of vascular events
MXPA03007462A (es) Uso de dipiridamol, acido acetilsalicilico y un antagonista de la angiotensina ii para el tratamiento y la prevencion de eventos vasculares.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)